Opinion|Videos|July 11, 2024
Evaluating Value of BTK Inhibitors in CLL Treatment
Experts evaluate the value of BTK inhibitors in CLL treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
2
Trump Childhood Vaccine Order: What It Means for Parents and Payers
3
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
4
Employers With Claims Data Access Take More Cost Action, Survey Finds
5